Reblozyl (luspatercept–aamt)

Bristol Myers Squibb

Pharma

BMS' blockbuster ambitions for Reblozyl narrowed slightly Monday

BMS' Reblozyl has stumbled on its quest to reach a wider pool of blood disorder patients.

Fraiser Kansteiner Jun 6, 2022 11:09am

Merck

Merck is axing 143 Acceleron positions after buyout

Mar 30, 2022 9:50am

yellow traffic light

The FDA delayed its decision date on a new nod for BMS' Reblozyl

Mar 25, 2022 9:55am